The Inclusive Trials Network
Enhancing access and diversity in medical research.
About Trial-Reach
Our Mission
At Trial-Reach, we strive to improve access to life-saving innovative treatments for patients across diverse backgrounds. Our mission is to ensure that clinical trials reflect real-world diversity by building clinical trial capabilities at healthcare sites in underserved communities.
Transforming Clinical Trial Access
Build Clinical Trial Site Hubs
We establish fully functional clinical trial site hubs within underserved community healthcare facilities that currently lack the financial resources, infrastructure, or staff capacity to participate in clinical research. These hubs are designed to plug in all necessary clinical trial capabilities—technology, staffing, regulatory processes, and operational workflows—enabling community-based sites to activate and run trials quickly and compliantly. Each hub is strategically built in partnership with a local academic medical center (AMC) to ensure access to specialized services, PI oversight, and patient safety support. This hub-and-spoke model allows us to decentralize clinical trial infrastructure, extend research into the communities where patients live, and create sustainable revenue streams for under-resourced hospitals.
Expand Access to Trials
We are addressing the longstanding inequity in clinical research by bringing trials directly to underserved and diverse communities that have historically been excluded from participation. By embedding clinical trial infrastructure into trusted, local healthcare settings—such as community hospitals and clinics—we reduce barriers like transportation, cost, language, and trust. Our model ensures that patients who are often overlooked in traditional trial recruitment can participate in cutting-edge treatments and contribute to the development of therapies that better reflect the real-world population. Through culturally competent care, logistical support services (e.g., childcare, mobile phlebotomy, home internet), and community engagement, we are creating a more inclusive research ecosystem where clinical trials are no longer a privilege of geography or socioeconomic status.
Support Clinical Trial Diversity Goals
Support Clinical Trial Diversity Goals
By reaching racially and ethnically diverse populations through trusted community health partners, we help ensure that new therapies are tested across a broad spectrum of genetic backgrounds and biological responses. This is critical to identifying population-specific efficacy, safety signals, and dosage needs—factors that can’t be captured in homogenous trial cohorts. Our infrastructure removes access barriers and accelerates recruitment from underserved populations, ensuring trials produce more generalizable, real-world-relevant results that support inclusive drug development and global market success.
Why It Matters
Widespread Access Gap
Health Systems and Non-Profits Must Lead the Way
Massive Growth in Trials
Despite the rapid growth in clinical trial activity, most Americans remain effectively locked out of participation. An estimated 88% of health centers across the U.S. lack the infrastructure—staff, technology, regulatory support, and financial resources—needed to conduct clinical trials. As a result, nearly 80% of patients have no practical access to research opportunities, especially those in rural, low-income, or historically underserved communities. This not only limits the diversity and representativeness of trial data but also deprives millions of patients of early access to potentially life-saving treatments. By decentralizing and democratizing trial infrastructure, we aim to close this gap and bring clinical research to where patients already receive care.
Massive Growth in Trials
Health Systems and Non-Profits Must Lead the Way
Massive Growth in Trials
The clinical research landscape is undergoing unprecedented expansion. Over the past decade, the number of new clinical trial starts has increased fivefold, driven by advances in precision medicine, rare disease research, and an influx of biotech innovation. At the same time, the demand for patient enrollment has skyrocketed—requiring 80 times more participants than before to adequately power these studies. This surge is creating enormous pressure on traditional trial sites, which are already strained and unable to meet enrollment targets. Without expanding access to new, community-based research sites, the industry faces delays, underpowered trials, and limited generalizability of data. We provide a scalable solution to absorb this growth and connect trials with the patients who need them most.
Health Systems and Non-Profits Must Lead the Way
Health Systems and Non-Profits Must Lead the Way
Health Systems and Non-Profits Must Lead the Way
Despite rapid advancements in medical research, fewer than 5% of U.S. patients ever participate in a clinical trial—largely because trials are inaccessible to the communities most in need. This lack of participation not only stalls innovation, costing up to $8 million per day in delayed revenue and time-to-market for new treatments, but also reinforces long-standing health disparities.
Nearly 75% of current trial participants are white, while Black, Hispanic, Asian, and other underrepresented communities remain excluded—limiting the applicability of research findings and perpetuating unequal health outcomes. Recognizing this, the FDA has issued clear guidance urging the inclusion of diverse populations in clinical research.
Health systems and non-profits are uniquely positioned to change this. By partnering to bring trials into trusted community sites, we can increase participation, improve health equity, and ensure new treatments are tested and proven effective across all populations—not just the privileged few.